Neuronascent Announces NIA Grant Award for NNI-362 to Reach Phase 2 Clinical Trials for Mild to Moderate Alzheimer’s Disease
Retrieved on:
Tuesday, August 22, 2023
The grant, titled “Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial,” will allow for the longer-term assessment of Neuronascent’s investigational drug, in a proof-of-concept clinical trial.
Key Points:
- The grant, titled “Completion of Non-clinical long-term GLP safety and GMP manufacture for first-in-class neuron regenerative therapy, NNI-362 Phase 2 POC AD trial,” will allow for the longer-term assessment of Neuronascent’s investigational drug, in a proof-of-concept clinical trial.
- Neuronascent discovered experimental therapeutic NNI-362 through a novel screening program aimed at identifying small molecules that should enter the human brain and promote new adult-born neurons to replace those lost in aging and disease.
- Key to its efficacy is the unique allosteric modulation of the pleiotropic kinase, p70S6 kinase, where this mechanism-of-action avoids the safety concerns observed with many kinase inhibitors.
- Neuronascent’s Dr. Kelleher-Andersson said, “With therapeutics that address the different stages of disease, we may finally be at the point of obtaining precision medicine for age-related neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease.”